PTEN and cancer: PTEN loss has been associated with ERG rearrangement [22] and adverse clinical course including post-PR upgrading [15], biochemical recurrence [23], progression after adjuvant treatment [24], as well as cancer-specific death in both hormone-naïve/hormone-sensitive [25], and castration-resistant patients [26].